High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center

Saved in:
Bibliographic Details
Published inBlood Vol. 120; no. 22; pp. 4445 - 4446
Main Authors Tsai, Stephanie B., Seldin, David C., Quillen, Karen, Berk, John L., Ruberg, Frederick L., Meier-Ewert, Hans, Sloan, J. Mark, Doros, Gheorghe, Finn, Kathleen T., Skinner, Martha, Sanchorawala, Vaishali
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 22.11.2012
Subjects
Adult
Aged
Amyloidosis - mortality
Amyloidosis - therapy
Cause of Death
Dose-Response Relationship, Drug
Drug-Related Side Effects and Adverse Reactions - epidemiology
Drug-Related Side Effects and Adverse Reactions - mortality
Hematopoietic Stem Cell Transplantation - mortality
Humans
Immunoglobulin Light Chains
Melphalan - administration & dosage
Melphalan - adverse effects
Middle Aged
Mortality - trends
Myeloablative Agonists - administration & dosage
Myeloablative Agonists - adverse effects
Tertiary Care Centers - statistics & numerical data
Time Factors
Online AccessGet full text

Cover

More Information
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2012-09-457341